Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Conditioning regimens in allo-SCT for thalassemia major.

Mathews V, Savani BN.

Bone Marrow Transplant. 2014 May;49(5):607-10. doi: 10.1038/bmt.2013.216. Epub 2014 Jan 20. Review.

PMID:
24442250
2.

Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.

Resnick IB, Aker M, Tsirigotis P, Shapira MY, Abdul-Hai A, Bitan M, Gesundheit B, Amar A, Ackerstein A, Samuel S, Slavin S, Or R.

Bone Marrow Transplant. 2007 Nov;40(10):957-64. Epub 2007 Sep 10.

PMID:
17846604
3.

Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.

Hussein AA, Al-Zaben A, Ghatasheh L, Natsheh A, Hammada T, Abdel-Rahman F, Abu-Jazar H, Sharma S, Najjar R, Frangoul H.

Pediatr Blood Cancer. 2013 Aug;60(8):1345-9. doi: 10.1002/pbc.24493. Epub 2013 Feb 19.

PMID:
23424175
4.

Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.

Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, Setia R, Katewa S.

Biol Blood Marrow Transplant. 2013 Mar;19(3):492-5. doi: 10.1016/j.bbmt.2012.11.007. Epub 2012 Nov 15.

5.

Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.

Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, Pagliara D, Contoli B, Pinto RM, Caocci G, Mastronuzzi A, La Nasa G, Locatelli F.

Blood. 2012 Jul 12;120(2):473-6. doi: 10.1182/blood-2012-04-423822. Epub 2012 May 29.

6.

Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.

Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou JF, Rossi JF.

Bone Marrow Transplant. 2001 Aug;28(4):335-9.

7.

Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.

Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Rodríguez F, López-Otero A, Herrera-Garza JL, Gómez-Almaguer D.

Ann Hematol. 2010 Oct;89(10):1045-52. doi: 10.1007/s00277-010-0986-1. Epub 2010 May 21.

PMID:
20490794
8.

Allogeneic stem cell transplantation in patients with β-thalassemia: King Faisal specialist hospital and research centre experience.

Al-Jefri A, Ayas A, Al Musa A, Al Mahr M, Al Saleh M, Rifai S, Sabbah R, Al Seraihy A, Al Ahmari A, Khairy E, Al Hassan I, El Solh H.

Hemoglobin. 2009;33 Suppl 1:S183-7. doi: 10.3109/03630260903351841.

PMID:
20001624
9.

Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning.

Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, Aoyama K, Iwasaki H, Miyamoto T, Hill GR, Akashi K, Teshima T.

Bone Marrow Transplant. 2014 Jan;49(1):110-5. doi: 10.1038/bmt.2013.134. Epub 2013 Sep 9.

PMID:
24013691
10.

Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies.

Sureda A, Schmitz N.

Ann Hematol. 2003 Jan;82(1):1-13. Epub 2003 Jan 9. Review.

PMID:
12574957
11.

Allogeneic stem cell transplantation for thalassemia major.

Mathews V, Srivastava A, Chandy M.

Hematol Oncol Clin North Am. 2014 Dec;28(6):1187-200. doi: 10.1016/j.hoc.2014.08.009. Epub 2014 Sep 22. Review.

PMID:
25459187
13.

[Reduced-intensity hematopoietic stem cell transplantation and donor lymphocyte infusions for chronic myeloid leukemia].

Ichinohe T, Ishikawa T.

Nihon Rinsho. 2003 Sep;61(9):1573-8. Review. Japanese.

PMID:
14515726
14.

Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF.

JAMA. 2014 Jul 2;312(1):48-56. doi: 10.1001/jama.2014.7192.

15.
16.

Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies.

Goussetis E, Efstathiou E, Paisiou A, Avgerinou G, Zisaki K, Giamouris VJ, Peristeri I, Kitra V, Vessalas G, Gamaletsou MN, Sipsas NV, Graphakos S.

Transpl Infect Dis. 2015 Apr;17(2):201-7. doi: 10.1111/tid.12358. Epub 2015 Mar 7.

PMID:
25645592
17.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

PMID:
11349810
18.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

19.

Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control.

Anurathapan U, Pakakasama S, Rujkijyanont P, Sirachainan N, Songdej D, Chuansumrit A, Sirireung S, Charoenkwan P, Jetsrisuparb A, Issaragrisil S, Ungkanont A, Sruamsiri R, Srisala S, Andersson BS, Hongeng S.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1259-62. doi: 10.1016/j.bbmt.2013.04.023. Epub 2013 May 3.

20.

Advantages and limitations of (non-)myeloablative allogeneic stem cell transplantation.

Huugen D, Schouten HC, Bos GM.

Neth J Med. 2002 May;60(4):162-9. Review.

Supplemental Content

Support Center